IL28B POLYMORPHISM AND KINETICS OF ANTIVIRAL ACTIVITY FOR ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 CHRONIC HCV PATIENTS

被引：0
|
作者：
Muir, Andrew J. [1 ]
Lawitz, Eric [2 ]
Rodriguez-Torres, Maribel
Rustgi, Vinod K. [3 ]
Hassanein, Tarek [4 ]
Appleman, James R. [5 ]
Crowley, Constance A. [5 ]
Freddo, James L. [5 ]
McHutchison, John G. [1 ]
机构：
[1] Duke Univ, Med Ctr, DCRI, Durham, NC USA
[2] Alamo Med Res, San Antonio, TX USA
[3] Metropolitan Res, Fairfax, VA USA
[4] SCTI Res Fdn, Ctr Liver, San Clemente, CA USA
[5] Anadys Pharmaceut Inc, San Diego, CA USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1852
引用
收藏
页码：1200A / 1200A
页数：1
相关论文
共 50 条
  • [21] The ENT1 polymorphism is not associated with anemia in HCV patients receiving pegylated interferon plus ribavirin, but identifies a subgroup of highly responsive HCV genotype 1/4 IL28B CC patients
    Galmozzi, Enrico
    Aghemo, Alessio
    Clark, Paul J.
    Degasperi, Elisabetta
    Rumi, Maria G.
    D'Ambrosio, Roberta
    Soffredini, Roberta
    Colombo, Massimo
    HEPATOLOGY, 2012, 56 : 996A - 997A
  • [22] Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4
    Rivero-Juarez, Antonio
    Camacho Espejo, Angela
    Perez-Camacho, Ines
    Neukam, Karin
    Caruz, Antonio
    Antonio Mira, Jose
    Mesa, Pilar
    Garcia-Lazaro, Milagros
    Torre-Cisneros, Julian
    Antonio Pineda, Juan
    Rivero, Antonio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (01) : 202 - 205
  • [23] A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naive patients with chronic hepatitis C
    Mangia, A
    Ricci, GL
    Persico, M
    Minerva, N
    Carretta, V
    Bacca, D
    Cela, M
    Piattelli, M
    Annese, M
    Maio, G
    Conte, D
    Guadagnino, V
    Pazienza, V
    Festi, D
    Spirito, F
    Andriulli, A
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (03) : 292 - 299
  • [24] ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS
    Lalezari, J.
    Poordad, F.
    Mehra, P.
    Nguyen, T.
    Dejesus, E.
    Godofsky, E.
    Patrick, G. Dubuc
    Chen, J.
    Pietropaolo, K.
    Zhou, X. -J.
    Sullivan-Bolyai, J. Z.
    Mayers, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S469 - S469
  • [25] Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV
    Villano, S. A.
    Raible, D.
    Harper, D.
    Speth, J.
    Chandra, P.
    Shaw, P.
    Bichier, G.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S24 - S24
  • [26] IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin
    Osinusi, Anu
    Chary, Aarthi
    Winters, Mark A.
    Naggie, Susanna
    Masur, Henry
    Polis, Michael A.
    Kottilil, Shyam
    Holodniy, Mark
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (10) : 1522 - 1527
  • [27] IL28B polymorphism and virological responseduring 12 weeks of pegylated interferon and ribavirin treatment in Polish chronic hepatitis C patients
    Swiatek, B.
    Januszkiewicz, D.
    Rembowska, J.
    Bereszynska, I.
    Kowala-Piaskowska, A.
    Mozer-Lisewska, I.
    Wysocki, J.
    Nowak, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 313 - 313
  • [28] Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism
    Ekstrom, Victoria
    Kumar, Rajneesh
    Zhao, Yi
    Yee, Mei Ling
    Sung, Cynthia
    Toh, Dorothy
    Loh, Poh Yen
    Tan, Jessica
    Teo, Eng Kiong
    Chow, Wan Cheng
    GASTROENTEROLOGY REPORT, 2017, 5 (03): : 208 - 212
  • [29] IMPACT OF IL28B POLYMORPHISM ON TREATMENT DURATION IN HCV GENOTYPE 1 AND 4 PATIENTS
    Scherzer, Thomas-Matthias
    Staettermayer, Albert
    Kessler, Harald H.
    Gschwantler, Michael
    Strasser, Michael P.
    Laferl, Hermann
    Maieron, Andreas
    Stauber, Rudolf E.
    Datz, Christian
    Rutter, Karoline
    Beinhardt, Sandra
    Steindl-Munda, Petra E.
    Hofer, Harald
    Ferenci, Peter
    HEPATOLOGY, 2010, 52 (04) : 765A - 765A
  • [30] IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
    Chayama, Kazuaki
    Hayes, C. Nelson
    Abe, Hiromi
    Miki, Daiki
    Ochi, Hidenori
    Karino, Yoshiyasu
    Toyota, Joji
    Nakamura, Yusuke
    Kamatani, Naoyuki
    Sezaki, Hitomi
    Kobayashi, Mariko
    Akuta, Norio
    Suzuki, Fumitaka
    Kumada, Hiromitsu
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (01): : 84 - 93
12345